Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Conditions

• Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• povorcitinib — DRUG
  Study drug will be taken orally as defined by the protocol.

Study Details

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Key Dates

Start date

Feb 28, 2025

Status verified

May 2026

Primary completion

Feb 28, 2028

Completion

Feb 28, 2028

Study Design

Enrollment

600 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: povorcitinib
  Participants will receive povorcitinib treatment with the same schedule and dose options as the study in which they originally enrolled.

Primary Outcome Measure

Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Up to approximately 3 years ]

Central Contacts

• Incyte Corporation Call Center (US)
  1.855.463.3463
  [email protected]
• Incyte Corporation Call Center (ex-US)
  +800 00027423
  [email protected]

Locations (108)

Find similar trials in Birmingham, AL

Related Studies

• Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
  EARLY_PHASE1 · Recruiting · Virginia Clinical Research, Inc. · Norfolk, Virginia
• Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
  PHASE2 · Recruiting · Zura Bio Inc · Phoenix, Arizona
• A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
  Recruiting · Sonoma Biotherapeutics, Inc. · San Francisco, California
• 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
  PHASE1 · Recruiting · Wynn Medical Center · Rosemead, California